Bench-to-bedside review: The role of nitric oxide in sepsis

Expert Review of Respiratory Medicine

Volumn 3, Issue 5, 2009, Pages 511-521

  De Cruz, Sharon J ^b   Kenyon, Nicholas J ^b   Sandrock, Christian E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acute lung injury; Acute respiratory distress syndrome; Constitutive nitric oxide synthase; Endothelial nitric oxide synthase; Hypoxic pulmonary vasoconstriction; Inducible nitric oxide synthase; Neuronal nitric oxide synthase; Nitric oxide; Nitric oxide synthase; Ventilation perfusion

Indexed keywords

1 AMINO 2 HYDROXYGUANIDINE; 2,4 DIAMINO 6 HYDROXYPYRIMIDINE; 7 CHLORO 3 IMINO 5 METHYL 2 AZABICYCLO[4.1.0]HEPTANE; AMINOETHYLISOTHIOURONIUM; AMINOGUANIDINE; CANAVANINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INDUCIBLE NITRIC OXIDE SYNTHASE; MERCAPTOETHYLGUANIDINE DERIVATIVE; METHYLISOTHIOUREA; N (1 IMINO 3 BUTENYL)ORNITHINE; N IMINOETHYLLYSINE; N OMEGA AMINOARGININE; N(G) METHYLARGININE; N(G) NITROARGININE; N(G) NITROARGININE METHYL ESTER; NEURONAL NITRIC OXIDE SYNTHASE; NEUROTRANSMITTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE INHIBITOR; PLACEBO; UNCLASSIFIED DRUG;

ACUTE LUNG INJURY; ADULT RESPIRATORY DISTRESS SYNDROME; CELL TYPE; CLINICAL TRIAL; DRUG EFFICACY; DRUG MECHANISM; ENZYME INHIBITION; HEART OUTPUT; HUMAN; HYPOXIA; INFLAMMATION; LUNG ALVEOLUS EPITHELIUM; LUNG ARTERY PRESSURE; LUNG CIRCULATION; LUNG VASOCONSTRICTION; MEAN ARTERIAL PRESSURE; MORTALITY; NONHUMAN; OXYGENATION; PATHOGENESIS; PULMONARY HYPERTENSION; REVIEW; SEPSIS; SURVIVAL; VASCULAR ENDOTHELIUM; VASODILATATION;

EID: 73449127635     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/ers.09.39     Document Type: Review

References (90)

1. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288(5789), 373-376 (1980).
2. Bonner FT. Nitric oxide gas. Methods Enzymol. 268, 50-57 (1996).
3. Hinder F, Stubbe HD, Van Aken H, Waurick R, Booke M, Meyer J. Role of nitric oxide in sepsis-associated pulmonary edema. Am. J. Respir. Crit. Care Med. 159(1), 252-257 (1999).
4. Ignarro LJ. Nitric oxide. A novel signal transduction mechanism for transcellular communication. Hypertension 16(5), 477-483 (1990).
5. Moncada S, Higgs A. The l-arginine-nitric oxide pathway. N. Engl. J. Med. 329(27), 2002-2012 (1993).
6. Singh S, Wort SJ, Evans TW. Inducible nitric oxide and pulmonary infection. Thorax 54(11), 959-960 (1999).
7. Marjanovic JA, Li Z, Stojanovic A, Du X. Stimulatory roles of nitric-oxide synthase 3 and guanylyl cyclase in platelet activation. J. Biol. Chem. 280(45), 37430-37438 (2005).
8. Denninger JW, Marletta MA. Guanylate cyclase and the .NO/cGMP signaling pathway. Biochim. Biophys. Acta 1411(2-3), 334-350 (1999).
9. Feihl F, Waeber B, Liaudet L. Is nitric oxide overproduction the target of choice for the management of septic shock? Pharmacol. Ther. 91(3), 179-213 (2001). • Review of the pharmacology and biochemistry of nitric oxide (NO), and the clinical and experimental data thus far.
10. Wallis G, Brackett D, Lerner M, Kotake Y, Bolli R, McCay PB. In vivo spin trapping of nitric oxide generated in the small intestine, liver, and kidney during the development of endotoxemia: a time-course study. Shock 6(4), 274-278 (1996).
11. Doughty LA, Kaplan SS, Carcillo JA. Inflammatory cytokine and nitric oxide responses in pediatric sepsis and organ failure. Crit. Care Med. 24(7), 1137-1143 (1996).
12. Groeneveld PH, Kwappenberg KM, Langermans JA, Nibbering PH, Curtis L. Nitric oxide (NO) production correlates with renal insufficiency and multiple organ dysfunction syndrome in severe sepsis. Intensive Care Med. 22(11), 1197-1202 (1996).
13. Griscavage JM, Hobbs AJ, Ignarro LJ. Negative modulation of nitric oxide synthase by nitric oxide and nitroso compounds. Adv. Pharmacol. 34, 215-234 (1995).
14. Rubbo H, Radi R, Trujillo M et al. Nitric oxide regulation of superoxide and peroxynitrite-dependent lipid peroxidation. Formation of novel nitrogen-containing oxidized lipid derivatives. J. Biol. Chem. 269(42), 26066-26075 (1994).
15. Wink DA, Mitchell JB. Chemical biology of nitric oxide: Insights into regulatory, cytotoxic, and cytoprotective mechanisms of nitric oxide. Free Radic. Biol. Med. 25(4-5), 434-456 (1998).
16. Vincent JL, Zhang H, Szabo C, Preiser JC. Effects of nitric oxide in septic shock. Am. J. Respir. Crit. Care Med. 161(6), 1781-1785 (2000). • Review of the role of NO on different organ systems in sepsis, based on experimental and clinical data.
17. Ghafourifar P, Schenk U, Klein SD, Richter C. Mitochondrial nitric-oxide synthase stimulation causes cytochrome c release from isolated mitochondria. Evidence for intramitochondrial peroxynitrite formation. J. Biol. Chem. 274(44), 31185-31188 (1999).
18. Ghafourifar P, Richter C. Mitochondrial nitric oxide synthase regulates mitochondrial matrix pH. Biol. Chem. 380(7-8), 1025-1028 (1999).
19. Bates TE, Loesch A, Burnstock G, Clark JB. Immunocytochemical evidence for a mitochondrially located nitric oxide synthase in brain and liver. Biochem. Biophys. Res. Commun. 213(3), 896-900 (1995).
20. Giulivi C, Poderoso JJ, Boveris A. Production of nitric oxide by mitochondria. J. Biol. Chem. 273(18), 11038-11043 (1998).
21. Lacza Z, Puskar M, Figueroa JP, Zhang J, Rajapakse N, Busija DW. Mitochondrial nitric oxide synthase is constitutively active and is functionally upregulated in hypoxia. Free Radic. Biol. Med. 31(12), 1609-1615 (2001).
22. Boveris A, Alvarez S, Navarro A. The role of mitochondrial nitric oxide synthase in inflammation and septic shock. Free Radic. Biol. Med. 33(9), 1186-1193 (2002).
23. Lancaster JR Jr, Hibbs JB Jr. EPR demonstration of iron-nitrosyl complex formation by cytotoxic activated macrophages. Proc. Natl Acad. Sci. USA 87(3), 1223-1227 (1990).
24. Beckmann JS, Ye YZ, Anderson PG et al. Extensive nitration of protein tyrosines in human atherosclerosis detected by immunohistochemistry. Biol. Chem. Hoppe Seyler 375(2), 81-88 (1994).
25. Eiserich JP, Hristova M, Cross CE et al. Formation of nitric oxide-derived inflammatory oxidants by myeloperoxidase in neutrophils. Nature 391(6665), 393-397 (1998).
26. Banan A, Fields JZ, Decker H, Zhang Y, Keshavarzian A. Nitric oxide and its metabolites mediate ethanol-induced microtubule disruption and intestinal barrier dysfunction. J. Pharmacol. Exp. Ther. 294(3), 997-1008 (2000).
27. Wink DA, Hanbauer I, Krishna MC, DeGraff W, Gamson J, Mitchell JB. Nitric oxide protects against cellular damage and cytotoxicity from reactive oxygen species. Proc. Natl Acad. Sci. USA 90(21), 9813-9817 (1993).
28. Ichihara A, Hayashi M, Navar LG, Saruta T. Inducible nitric oxide synthase attenuates endothelium-dependent renal microvascular vasodilation. J. Am. Soc. Nephrol. 11(10), 1807-1812 (2000).
29. Spain DA, Wilson MA, Bloom IT, Garrison RN. Renal microvascular responses to sepsis are dependent on nitric oxide. J. Surg. Res. 56(6), 524-529 (1994).
30. Wu CC, Ruetten H, Thiemermann C. Comparison of the effects of aminoguanidine and N omega-nitro-l -arginine methyl ester on the multiple organ dysfunction caused by endotoxaemia in the rat. Eur. J. Pharmacol. 300(1-2), 99-104 (1996).
31. Hinshaw LB. Sepsis/septic shock: participation of the microcirculation: an abbreviated review. Crit. Care Med. 24(6), 1072-1078 (1996).
32. Beach PK, Spain DA, Kawabe T, Harris PD, Garrison RN. Sepsis increases NOS-2 activity and decreases non-NOS-mediated acetylcholine-induced dilation in rat aorta. J. Surg. Res. 96(1), 17-22 (2001).
33. Avontuur JA, Bruining HA, Ince C. Inhibition of nitric oxide synthesis causes myocardial ischemia in endotoxemic rats. Circ. Res. 76(3), 418-425 (1995).
34. Brady AJ. Nitric oxide, myocardial failure and septic shock. Int. J. Cardiol. 50(3), 269-272 (1995).
35. Petros A, Lamb G, Leone A, Moncada S, Bennett D, Vallance P. Effects of a nitric oxide synthase inhibitor in humans with septic shock. Cardiovasc. Res. 28(1), 34-39 (1994).
36. Avontuur JA, Biewenga M, Buijk SL, Kanhai KJ, Bruining HA. Pulmonary hypertension and reduced cardiac output during inhibition of nitric oxide synthesis in human septic shock. Shock 9(6), 451-454 (1998).
37. Offner PJ, Ogura H, Jordan BS, Pruitt BA Jr, Cioffi WG. Cardiopulmonary effects of combined nitric oxide inhibition and inhaled nitric oxide in porcine endotoxic shock. J. Trauma 41(4), 641-646 (1996).
38. Cohen RI, Shapir Y, Chen L, Scharf SM. Right ventricular overload causes the decrease in cardiac output after nitric oxide synthesis inhibition in endotoxemia. Crit. Care Med. 26(4), 738-747 (1998).
39. Uchida T, Ichikawa K, Yokoyama K, Mitaka C, Toyooka H, Amaha K. Inhaled nitric oxide improved the outcome of severe right ventricular failure caused by lipopolysaccharide administration. Intensive Care Med. 22(11), 1203-1206 (1996).
40. Salzman AL, Menconi MJ, Unno N et al. Nitric oxide dilates tight junctions and depletes ATP in cultured Caco-2BBe intestinal epithelial monolayers. Am. J. Physiol. 268(2 Pt 1), G361-G373 (1995).
41. Zhang H, Rogiers P, Smail N et al. Effects of nitric oxide on blood flow distribution and O2 extraction capabilities during endotoxic shock. J. Appl. Physiol. 83(4), 1164-1173 (1997).
42. Kantrow SP, Taylor DE, Carraway MS, Piantadosi CA. Oxidative metabolism in rat hepatocytes and mitochondria during sepsis. Arch. Biochem. Biophys. 345(2), 278-288 (1997).
43. Sarady JK, Zuckerbraun BS, Bilban M et al. Carbon monoxide protection against endotoxic shock involves reciprocal effects on iNOS in the lung and liver. FASEB J. 18(7), 854-856 (2004).
44. Kadoi Y, Goto F. Selective inducible nitric oxide inhibition can restore hemodynamics, but does not improve neurological dysfunction in experimentally-induced septic shock in rats. Anesth. Analg. 99(1), 212-220 (2004).
45. Harada S, Imaki T, Chikada N, Naruse M, Demura H. Distinct distribution and time-course changes in neuronal nitric oxide synthase and inducible NOS in the paraventricular nucleus following lipopolysaccharide injection. Brain Res. 821(2), 322-332 (1999).
46. Rottenberg ME, Gigliotti Rothfuchs AC, Gigliotti D, Svanholm C, Bandholtz L, Wigzell H. Role of innate and adaptive immunity in the outcome of primary infection with Chlamydia pneumoniae, as analyzed in genetically modified mice. J. Immunol. 162(5), 2829-2836 (1999).
47. Heath L, Chrisp C, Huffnagle G et al. Effector mechanisms responsible for γ interferon-mediated host resistance to Legionella pneumophila lung infection: the role of endogenous nitric oxide differs in susceptible and resistant murine hosts. Infect. Immun. 64(12), 5151-5160 (1996).
48. MacMicking JD, North RJ, LaCourse R, Mudgett JS, Shah SK, Nathan CF. Identification of nitric oxide synthase as a protective locus against tuberculosis. Proc. Natl Acad. Sci. USA 94(10), 5243-5248 (1997).
49. Van Dervort AL, Yan L, Madara PJ et al. Nitric oxide regulates endotoxin-induced TNF-a production by human neutrophils. J. Immunol. 152(8), 4102-4109 (1994).
50. Akaike T, Noguchi Y, Ijiri S et al. Pathogenesis of influenza virus-induced pneumonia: involvement of both nitric oxide and oxygen radicals. Proc. Natl Acad. Sci. USA 93(6), 2448-2453 (1996).
51. Kristof AS, Goldberg P, Laubach V, Hussain SN. Role of inducible nitric oxide synthase in endotoxin-induced acute lung injury. Am. J. Respir. Crit. Care Med. 158(6), 1883-1889 (1998).
52. McClintock DE, Ware LB, Eisner MD, Wickersham N, Thompson BT, Matthay MA. Higher urine nitric oxide is associated with improved outcomes in patients with acute lung injury. Am. J. Respir. Crit. Care Med. 175(3), 256-262 (2007).
53. Wang le F, Patel M, Razavi HM et al. Role of inducible nitric oxide synthase in pulmonary microvascular protein leak in murine sepsis. Am. J. Respir. Crit. Care Med. 165(12), 1634-1639 (2002).
54. Mathrani VC, Kenyon NJ, Zeki A, Last JA. Mouse models of asthma: can they give us mechanistic insights into the role of nitric oxide? Curr. Med. Chem. 14(20), 2204-2213 (2007). • Role of NO in allergic airway inflammation.
55. Fischer A, Folkerts G, Geppetti P, Groneberg DA. Mediators of asthma: nitric oxide. Pulm Pharmacol. Ther. 15(2), 73-81 (2002).
56. Skidgel RA, Gao XP, Brovkovych V et al. Nitric oxide stimulates macrophage inflammatory protein-2 expression in sepsis. J. Immunol. 169(4), 2093-2101 (2002).
57. Suzuki S, Togari H, Yamaguchi N, Haas KM. Nitric oxide inhalation and nitric oxide synthase inhibitor supplement for endotoxin-induced hypotension. Pediatr. Int. 43(4), 343-349 (2001). • Experimental study evaluating the role of inhaled NO and nonspecific NOS inhibitor in refractory hypotension and pulmonary hypertension.
58. Rimar S, Gillis CN. Selective pulmonary vasodilation by inhaled nitric oxide is due to hemoglobin inactivation. Circulation 88(6), 2884-2887 (1993).
59. Pison U, Lopez FA, Heidelmeyer CF, Rossaint R, Falke KJ. Inhaled nitric oxide reverses hypoxic pulmonary vasoconstriction without impairing gas exchange. J. Appl. Physiol. 74(3), 1287-1292 (1993).
60. Putensen C, Rasanen J, Downs JB. Effect of endogenous and inhaled nitric oxide on the ventilation-perfusion relationships in oleic-acid lung injury. Am. J. Respir. Crit. Care Med. 150(2), 330-336 (1994).
61. Kostler WJ, Rabitsch W, Locker GJ et al. Influence of inhaled nitric oxide on plasma nitrate concentrations in patients with adult respiratory distress syndrome and sepsis: results of a pilot study. J. Clin. Anesth. 18(3), 179-184 (2006).
62. Rossaint R, Falke KJ, Lopez F, Slama K, Pison U, Zapol WM. Inhaled nitric oxide for the adult respiratory distress syndrome. N. Engl. J. Med. 328(6), 399-405 (1993).
63. Pepke-Zaba J, Higenbottam TW, Dinh-Xuan AT, Stone D, Wallwork J. Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension. Lancet 338(8776), 1173-1174 (1991).
64. Krafft P, Fridrich P, Fitzgerald RD, Koc D, Steltzer H. Effectiveness of nitric oxide inhalation in septic ARDS. Chest 109(2), 486-493 (1996).
65. Dellinger RP, Zimmerman JL, Taylor RW et al. Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: results of a randomized Phase II trial. Inhaled Nitric Oxide in ARDS Study Group. Crit. Care Med. 26(1), 15-23 (1998).
66. Lundin S, Mang H, Smithies M, Stenqvist O, Frostell C. Inhalation of nitric oxide in acute lung injury: results of a European multicentre study. The European Study Group of Inhaled Nitric Oxide. Intensive Care Med. 25(9), 911-919 (1999).
67. Adhikari NK, Burns KE, Friedrich JO, Granton JT, Cook DJ, Meade MO. Effect of nitric oxide on oxygenation and mortality in acute lung injury: systematic review and meta-analysis. BMJ 334(7597), 779 (2007).
68. Cobb JP, Natanson C, Hoffman WD et al. N omega-amino-l-arginine, an inhibitor of nitric oxide synthase, raises vascular resistance but increases mortality rates in awake canines challenged with endotoxin. J. Exp. Med. 176(4), 1175-1182 (1992).
69. Liaudet L, Rosselet A, Schaller MD, Markert M, Perret C, Feihl F. Nonselective versus selective inhibition of inducible nitric oxide synthase in experimental endotoxic shock. J. Infect. Dis. 177(1), 127-132 (1998).
70. Avontuur JA, Tutein Nolthenius RP, van Bodegom JW, Bruining HA. Prolonged inhibition of nitric oxide synthesis in severe septic shock: a clinical study. Crit. Care Med. 26(4), 660-667 (1998).
71. Spain DA, Wilson MA, Bar-Natan MF, Garrison RN. Nitric oxide synthase inhibition aggravates intestinal microvascular vasoconstriction and hypoperfusion of bacteremia. J. Trauma 36(5), 720-725 (1994).
72. Lorente JA, Landin L, De Pablo R, Renes E, Liste D. l-arginine pathway in the sepsis syndrome. Crit. Care Med. 21(9), 1287-1295 (1993).
73. Grover R, Zaccardelli D, Colice G, Guntupalli K, Watson D, Vincent JL. An open-label dose escalation study of the nitric oxide synthase inhibitor, N(G)-methyl- l-arginine hydrochloride (546C88), in patients with septic shock. Glaxo Wellcome International Septic Shock Study Group. Crit. Care Med. 27(5), 913-922 (1999). • Large multicenter trial showing reduction in catecholamine dosage required for hemodynamic support in patients given a nonspecific NOS inhibitor.
74. Grover R, Bakker J, McLuckie et al. The nitric oxide synthase inhibitor 546C88 promotes the resolution of shock in patients with severe sepsis. Crit. Care Med. 26(Suppl.), A29 (1998). • Large multicenter trial that showed that more patients in the treatment group had resolution of sepsis at 72 h.
75. No Authors Listed: Society of Critical Care Medicine 27th Educational and Scientific Symposium. San Antonio, Texas, USA, February 4-8, 1998. Abstracts. Crit. Care Med. 26(1 Suppl.), A5-A149 (1998).
76. Grover R, Lopez A, Lorente J et al. Multi-center, randomized, placebocontrolled, double blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit. Care Med. 27(Suppl.), A33 (1999). • Large multicenter trial that showed increased mortality in the group receiving nonspecific NOS inhibitors, and was discontinued early.
77. No Authors Listed: Society of Critical Care Medicine 28th Educational and Scientific Symposium. San Francisco, California, USA. January 23-27, 1999. Abstracts. Crit. Care Med. 27(1 Suppl.), A27-A194 (1999).
78. Schwartz D, Mendonca M, Schwartz I et al. Inhibition of constitutive nitric oxide synthase (NOS) by nitric oxide generated by inducible NOS after lipopolysaccharide administration provokes renal dysfunction in rats. J. Clin. Invest. 100(2), 439-448 (1997).
79. Fischer LG, Horstman DJ, Hahnenkamp K, Kechner NE, Rich GF. Selective iNOS inhibition attenuates acetylcholine- and bradykinin-induced vasoconstriction in lipopolysaccharide-exposed rat lungs. Anesthesiology 91(6), 1724-1732 (1999).
80. Wei XQ, Charles IG, Smith A et al. Altered immune responses in mice lacking inducible nitric oxide synthase. Nature 375(6530), 408-411 (1995).
81. Gunnett CA, Chu Y, Heistad DD, Loihl A, Faraci FM. Vascular effects of LPS in mice deficient in expression of the gene for inducible nitric oxide synthase. Am. J. Physiol. 275(2 Pt 2), H416-H421 (1998).
82. Ruetten H, Southan GJ, Abate A, Thiemermann C. Attenuation of endotoxin-induced multiple organ dysfunction by 1-amino-2-hydroxyguanidine, a potent inhibitor of inducible nitric oxide synthase. Br. J. Pharmacol. 118(2), 261-270 (1996).
83. Liaudet L, Feihl F, Rosselet A, Markert M, Hurni JM, Perret C. Beneficial effects of l-canavanine, a selective inhibitor of inducible nitric oxide synthase, during rodent endotoxaemia. Clin. Sci. (Lond.) 90(5), 369-377 (1996).
84. Fishman D, Liaudet L, Lazor R, Perret CH, Feihl F. l-canavanine, an inhibitor of inducible nitric oxide synthase, improves venous return in endotoxemic rats. Crit. Care Med. 25(3), 469-475 (1997).
85. Heremans H, Dillen C, Groenen M, Matthys P, Billiau A. Role of interferon-γ and nitric oxide in pulmonary edema and death induced by lipopolysaccharide. Am. J. Respir. Crit. Care Med. 161(1), 110-117 (2000).
86. Arkovitz MS, Wispe JR, Garcia VF, Szabo C. Selective inhibition of the inducible isoform of nitric oxide synthase prevents pulmonary transvascular flux during acute endotoxemia. J. Pediatr. Surg. 31(8), 1009-1015 (1996).
87. Okamoto I, Abe M, Shibata K et al. Evaluating the role of inducible nitric oxide synthase using a novel and selective inducible nitric oxide synthase inhibitor in septic lung injury produced by cecal ligation and puncture. Am. J. Respir. Crit. Care Med. 162(2 Pt 1), 716-722 (2000).
88. Benjamim CF, Silva JS, Fortes ZB, Oliveira MA, Ferreira SH, Cunha FQ. Inhibition of leukocyte rolling by nitric oxide during sepsis leads to reduced migration of active microbicidal neutrophils. Infect. Immun. 70(7), 3602-3610 (2002).
89. Aranow JS, Zhuang J, Wang H, Larkin V, Smith M, Fink MP. A selective inhibitor of inducible in nitric oxide synthase prolongs survival in a rat model of bacterial peritonitis: comparison with two nonselective strategies. Shock 5(2), 116-121 (1996).
90. Suffredini AF, Fromm RE, Parker MM et al. The cardiovascular response of normal humans to the administration of endotoxin. N. Engl. J. Med. 321(5), 280-287 (1989).